Vaccines and diagnostics for the ehrlichioses
US-10131705-B2 · Nov 20, 2018 · US
Vaccines and diagnostics for the ehrlichioses
US9605035B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605035-B2 |
| Application number | US-81236509-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 9, 2009 |
| Priority date | Jan 10, 2008 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide composition comprising one or more of the following: (a) an isolated polypeptide that is no more than 50 amino acids in length comprising one or more amino acid sequences selected from the group consisting of: SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; and SEQ ID NO:11; or (b) an isolated polypeptide that is at least 95% identical to the polypeptide of (a); and wherein the one or more isolated polypeptide(s) are bound to a solid support. 2. The polypeptide composition of claim 1 , wherein said isolated polypeptide is dispersed in a pharmaceutically acceptable diluent. 3. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence selected from the group consisting of: SEQ ID NO:3 and SEQ ID NO:4. 4. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence selected from the group consisting of: SEQ ID NO: 8; SEQ ID NO:9; SEQ ID NO:10; and SEQ ID NO:11. 5. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:8. 6. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:9. 7. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:10. 8. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:11. 9. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:3. 10. The composition of claim 1 , wherein the polypeptide of (a) comprises the amino acid sequence SEQ ID NO:4. 11. A kit, housed in a suitable container, comprising the polypeptide composition of claim 1 . 12. The polypeptide composition of claim 1 , wherein the isolated polypeptide consists of one or more amino acid sequences selected from the group consisting of: SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; and SEQ ID NO:11. 13. The polypeptide composition of claim 1 , wherein the isolated polypeptide is less than 30 amino acids in length and comprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; and SEQ ID NO:11; or (b) an isolated polypeptide that is at least 95% identical to the polypeptide of (a). 14. The polypeptide composition of claim 1 , wherein the solid support is a microtiter well, nitrocellulose sheet, immunoblot membrane or column matrix.
Assignees
Inventors
Classifications
Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof · CPC title
from Richettsiales (o) · CPC title
Rickettsiales, e.g. Anaplasma · CPC title
Bacteria · CPC title
Antiparasitic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9605035B2 cover?
- The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
- Who is the assignee on this patent?
- Mcbride Jere W, Luo Tian, Res Dev Foundation
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1246. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).